Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection
Man-Fung Yuen,Seng-Gee Lim,Robert Plesniak,Keiji Tsuji,Harry L A Janssen,Cristina Pojoga,Adrian Gadano,Corneliu P Popescu,Tatyana Stepanova,Tarik Asselah,Gheorghe Diaconescu,Hyung Joon Yim,Jeong Heo,Ewa Janczewska,Alexander Wong,Nevin Idriz,Michio Imamura,Giuliano Rizzardini,Koichi Takaguchi,Pietro Andreone,Manuela Arbune,Jinlin Hou,Sung Jae Park,Andrei Vata,Jennifer Cremer,Robert Elston,Tamara Lukić,Geoff Quinn,Lauren Maynard,Stuart Kendrick,Helene Plein,Fiona Campbell,Melanie Paff,Dickens Theodore,B-Clear Study Group,Luis Colombato,Jordan Genov,Dimitar Pavlov,Diana Petrova,Konstantin Tchernev,Carla Coffin,Wayne Ghesquiere,Harry Janssen,Paul Marotta,Sebastien Poulin,Marie-Louise Vachon,Xiaoguang Dou,Jidong Jia,Qin Ning,Hong Ren,Guiqiang Wang,Qing Xie,Wen Xie,Vincent Leroy,Véronique Loustaud-Ratti,Lawrence Serfaty,Albert Tran,Fabien Zoulim,Jukka Hartikainen,Andreas Kremer,Thomas Lutz,Michael Sabranski,Kathrin Sprinzl,Man Fung Yuen,Pietro Lampertico,Massimo Memoli,Tomofumi Atarashi,Masanori Atsukawa,Shigetoshi Fujiyama,Jun Inoue,Kouji Joko,Kaheita Kakinoki,Atsumasa Komori,Takuya Komura,Masayuki Kurosaki,Tetsuo Takehara,Yasuhito Tanaka,Muhammad Firdaus Md Salleh,Rosmawati Mohamed,Felix Domingo Jr,Madalinee Eternity Labio,Jan Gietka,Krzysztof Tomasiewicz,Hyung Joon Kim,Ju Hyun Kim,Yoon Jun Kim,YoungOh Kweon,Young-Suk Lim,Neung Hwa Park,Sung-Jae Park,Dana Crisan,Iosif Marincu,Adrian Moraru,Corneliu Popescu,Pavel Bogomolov,Natalya Gankina,Denis Gusev,Vyacheslav Morozov,Marina Osipenko,Vladimir Rafalsky,Svetlana Romanova,Olga Sagalova,Natalya Voloshina,Sergey Zotov,Rajneesh Kumar,Jessica Tan,Primrose Mabale,Rosie Mngqibisa,Naeem Moosa,Zelda Punt,Agatha Wilhase,Sabelo Xaba,Javier Ampuero Herrojo,Raul Andrade Bellido,Maria Buti,José Luís Calleja Panero,Javier Crespo,Xavier Forns Bernhardt,Javier Garcia Samaniego,Pablo Ryan Murua,Raymond Chung,Michael Fuchs,Binu John,James Park,Mordechai Rabinovitz,David Rausher,Eugene Schiff,Norah Terrault
DOI: https://doi.org/10.1056/NEJMoa2210027
2022-11-24
Abstract:Background: Bepirovirsen is an antisense oligonucleotide that targets all hepatitis B virus (HBV) messenger RNAs and acts to decrease levels of viral proteins. Methods: We conducted a phase 2b, randomized, investigator-unblinded trial involving participants with chronic HBV infection who were receiving or not receiving nucleoside or nucleotide analogue (NA) therapy. Participants were randomly assigned (in a 3:3:3:1 ratio) to receive weekly subcutaneous injections of bepirovirsen at a dose of 300 mg for 24 weeks (group 1), bepirovirsen at a dose of 300 mg for 12 weeks then 150 mg for 12 weeks (group 2), bepirovirsen at a dose of 300 mg for 12 weeks then placebo for 12 weeks (group 3), or placebo for 12 weeks then bepirovirsen at a dose of 300 mg for 12 weeks (group 4). Groups 1, 2, and 3 received loading doses of bepirovirsen. The composite primary outcome was a hepatitis B surface antigen (HBsAg) level below the limit of detection and an HBV DNA level below the limit of quantification maintained for 24 weeks after the planned end of bepirovirsen treatment, without newly initiated antiviral medication. Results: The intention-to-treat population comprised 457 participants (227 receiving NA therapy and 230 not receiving NA therapy). Among those receiving NA therapy, a primary-outcome event occurred in 6 participants (9%; 95% credible interval, 0 to 31) in group 1, in 6 (9%; 95% credible interval, 0 to 43) in group 2, in 2 (3%; 95% credible interval, 0 to 16) in group 3, and 0 (0%; post hoc credible interval, 0 to 8) in group 4. Among participants not receiving NA therapy, a primary-outcome event occurred in 7 participants (10%; 95% credible interval, 0 to 38), 4 (6%; 95% credible interval, 0 to 25), 1 (1%; post hoc credible interval, 0 to 6), and 0 (0%; post hoc credible interval, 0 to 8), respectively. During weeks 1 through 12, adverse events, including injection-site reactions, pyrexia, fatigue, and increased alanine aminotransferase levels, were more common with bepirovirsen (groups 1, 2, and 3) than with placebo (group 4). Conclusions: In this phase 2b trial, bepirovirsen at a dose of 300 mg per week for 24 weeks resulted in sustained HBsAg and HBV DNA loss in 9 to 10% of participants with chronic HBV infection. Larger and longer trials are required to assess the efficacy and safety of bepirovirsen. (Funded by GSK; B-Clear ClinicalTrials.gov number, NCT04449029.).